Contact
searchSearch
HMP Global
Login
Infographic

Subcutaneous Immunotherapy in Genitourinary Cancer

07/30/2026


This infographic provides a visual overview of the approved subcutaneous anti-PD-1 options for genitourinary cancers, highlighting supporting trial data, time-saving advantages for patients, and operational considerations for implementing subcutaneous immunotherapy in the clinic.

© 2026 HMP Global. All Rights Reserved.

Related Content

Doctor with syringe
Special Article
Subcutaneous Immunotherapy in Genitourinary Cancer: Clinical Context, Patient Considerations, and Practice Integration
07/30/2026
This article reviews the current standard and subcutaneous immunotherapy options for renal cell carcinoma and bladder cancer, and outlines the patient-facing benefits and practical steps for integrating subcutaneous administration into...
This article reviews the current standard and subcutaneous immunotherapy options for renal cell carcinoma and bladder cancer, and outlines the patient-facing benefits and practical steps for integrating subcutaneous administration into...
This article reviews the current...
07/30/2026
Oncology
Thumbnail
Videos
How to Implement Subcutaneous Immunotherapy for Providers
07/30/2026
Meagan Farnie, BSN, RN; Pablo Saenz, PharmD; Dean Tuel; Jeff Yorio, MD
The panel outlines how to operationalize subcutaneous immunotherapy in clinical practice, covering efficacy and safety review, insurance and workflow considerations, and strategies for educating patients and care teams during the transition.
The panel outlines how to operationalize subcutaneous immunotherapy in clinical practice, covering efficacy and safety review, insurance and workflow considerations, and strategies for educating patients and care teams during the transition.
The panel outlines how to...
07/30/2026
Oncology
Thumbnail
Videos
Advantages of Subcutaneous Immunotherapy for Patients 
07/30/2026
Meagan Farnie, BSN, RN; Pablo Saenz, PharmD; Dean Tuel; Jeff Yorio, MD
Experts and a patient discuss the practical advantages of subcutaneous immunotherapy for genitourinary cancers, including reduced chair time, less discomfort, and the resulting impact on patient quality of life and treatment burden.
Experts and a patient discuss the practical advantages of subcutaneous immunotherapy for genitourinary cancers, including reduced chair time, less discomfort, and the resulting impact on patient quality of life and treatment burden.
Experts and a patient discuss...
07/30/2026
Oncology
Thumbnail
Videos
Subcutaneous Immunotherapy Options Available for Genitourinary Cancer
07/30/2026
Meagan Farnie, BSN, RN; Pablo Saenz, PharmD; Dean Tuel; Jeff Yorio, MD
The panel reviews the clinical data behind subcutaneous pembrolizumab and nivolumab, comparing efficacy and pharmacokinetics to their IV counterparts, and shares early clinical impressions of introducing these formulations into practice.
The panel reviews the clinical data behind subcutaneous pembrolizumab and nivolumab, comparing efficacy and pharmacokinetics to their IV counterparts, and shares early clinical impressions of introducing these formulations into practice.
The panel reviews the clinical...
07/30/2026
Oncology

More in This Series:

Infographic preview
Infographic
Subcutaneous Immunotherapy in Genitourinary Cancer
07/30/2026
This infographic provides a visual overview of the approved subcutaneous anti-PD-1 options for genitourinary cancers, highlighting supporting trial data, time-saving advantages for patients, and operational considerations for implementing...
This infographic provides a visual overview of the approved subcutaneous anti-PD-1 options for genitourinary cancers, highlighting supporting trial data, time-saving advantages for patients, and operational considerations for implementing...
This infographic provides a...
07/30/2026
Oncology
Doctor with syringe
Special Article
Subcutaneous Immunotherapy in Genitourinary Cancer: Clinical Context, Patient Considerations, and Practice Integration
07/30/2026
This article reviews the current standard and subcutaneous immunotherapy options for renal cell carcinoma and bladder cancer, and outlines the patient-facing benefits and practical steps for integrating subcutaneous administration into...
This article reviews the current standard and subcutaneous immunotherapy options for renal cell carcinoma and bladder cancer, and outlines the patient-facing benefits and practical steps for integrating subcutaneous administration into...
This article reviews the current...
07/30/2026
Oncology
Thumbnail
Videos
How to Implement Subcutaneous Immunotherapy for Providers
07/30/2026
Meagan Farnie, BSN, RN; Pablo Saenz, PharmD; Dean Tuel; Jeff Yorio, MD
The panel outlines how to operationalize subcutaneous immunotherapy in clinical practice, covering efficacy and safety review, insurance and workflow considerations, and strategies for educating patients and care teams during the transition.
The panel outlines how to operationalize subcutaneous immunotherapy in clinical practice, covering efficacy and safety review, insurance and workflow considerations, and strategies for educating patients and care teams during the transition.
The panel outlines how to...
07/30/2026
Oncology
Thumbnail
Videos
How to Implement Subcutaneous Immunotherapy for Providers
07/30/2026
Meagan Farnie, BSN, RN; Pablo Saenz, PharmD; Dean Tuel; Jeff Yorio, MD
The panel outlines how to operationalize subcutaneous immunotherapy in clinical practice, covering efficacy and safety review, insurance and workflow considerations, and strategies for educating patients and care teams during the transition.
The panel outlines how to operationalize subcutaneous immunotherapy in clinical practice, covering efficacy and safety review, insurance and workflow considerations, and strategies for educating patients and care teams during the transition.
The panel outlines how to...
07/30/2026
Oncology
Thumbnail
Videos
Advantages of Subcutaneous Immunotherapy for Patients 
07/30/2026
Meagan Farnie, BSN, RN; Pablo Saenz, PharmD; Dean Tuel; Jeff Yorio, MD
Experts and a patient discuss the practical advantages of subcutaneous immunotherapy for genitourinary cancers, including reduced chair time, less discomfort, and the resulting impact on patient quality of life and treatment burden.
Experts and a patient discuss the practical advantages of subcutaneous immunotherapy for genitourinary cancers, including reduced chair time, less discomfort, and the resulting impact on patient quality of life and treatment burden.
Experts and a patient discuss...
07/30/2026
Oncology

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use